Reassuring new data on statin-induced Lp(a) elevation
Statin therapy is known to raise Lp(a) particle concentration in some patients, but how does this impact the overall effect of these medications on ASCVD risk?
#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
“Not everybody dies from atherosclerosis, but… everybody dies with it.” —Peter Attia
Muscle Mass and Cognitive Function
A recent narrative review hypothesizes a key role for myokine disruption caused by physical inactivity.
Confusion over results of a recent colonoscopy trial
A recently published NEJM paper appears to show that colonoscopy screenings do not reduce risk of colorectal cancer death. As is often the case, the results have been taken out of context and their implications grossly overestimated.
The genetics of PCSK9i nonresponders
A recent case study shines light on why some individuals are resistant to PCSK9 inhibitors.
Adding context to the Alzheimer’s disease research fraud charges
This past July, a news article published in Science sent shockwaves through the scientific community when it reported that one of the most influential and frequently-cited publications in Alzheimer’s disease (AD) research was evidently based on fraud.
First Case of Human PCSK9 Gene-Editing
Ultimately, the long-term benefits of lowering apoB through a one-time treatment may make this not only a viable future option, but potentially an intervention that could change preventive cardiovascular medicine.
Comment policyComments are welcomed and encouraged on this site, but there are some instances where comments will be edited or deleted as follows: